Kuros Biosciences AG / Key word(s): Miscellaneous Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement", respectively). The New Shares have been placed at a price of CHF 1.60 each, including nominal value and share premium (the "Subscription Price"). "Successfully completing this private placement provides Kuros with the ability to extend its operating runway into the second quarter of 2024, covering results of the Phase 2 trial of Fibrin-PTH in spinal fusion and enabling us to complete the preparatory work for Phase 3 with this program," said Joost de Bruijn, Chief Executive Officer of Kuros. "It will also support continuing clinical development of our MagnetOs bone graft and its accelerating commercialization." The Placement was implemented with two investors, namely Optiverder B.V., Delft, The Netherlands and Pegasus Global Opportunity Fund Ltd., a fund domiciled in the British Virgin Islands managed by Alpha Capital AG, Zurich, Switzerland. The New Shares represent 11.4% of the Company’s share capital prior to the Placement on a non-diluted basis. Following the registration of the capital increase by the commercial register of Zurich, expected to occur on September 15, 2022, the Company’s share capital will be composed of 36,561,378 shares with a nominal value of CHF 0.10 each. Pursuant to applicable Swiss law, the capital increase has been implemented out of the Kuros' authorized share capital pursuant to article 3d of the articles of association. In order to raise this capital in a quick and flexible manner, the subscription rights of existing shareholders have been excluded. The Subscription Price represents a discount of 10.1% on the closing market price, respectively 5.6% on the 14 days VWAP (Volume Weighted Average Price) of the Company’s shares on SIX Swiss Exchange on the last trading day preceding the closing date of the Offering, i.e. CHF 1.78 (market price), respectively 1.69 CHF (14 days VWAP) on September 14, 2022. The listing and first day of trading of the new registered shares on the SIX Swiss Exchange are expected to take place on September 16, 2022. The New Shares will carry immediate dividend and voting rights. For further information, please contact:
About Kuros Biosciences AG Forward Looking Statements End of Inside Information |
Language: | English |
Company: | Kuros Biosciences AG |
Wagistrasse 25 | |
8952 Schlieren | |
Switzerland | |
Phone: | +41 44 733 4747 |
Fax: | +41 44 733 4740 |
E-mail: | info@kurosbio.com |
Internet: | www.kurosbio.com |
ISIN: | CH0325814116 |
Valor: | 32581411 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1442853 |
End of Announcement | EQS News Service |
|
1442853 15-Sep-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.